BridgeBio Pharma, Inc.
$74.02
▼
-2.84%
2026-04-22 10:12:13
bridgebio.com
NMS: BBIO
Explore BridgeBio Pharma, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$14.41 B
Current Price
$74.02
52W High / Low
$84.94 / $31.77
Stock P/E
—
Book Value
$-10.71
Dividend Yield
—
ROCE
-77.47%
ROE
40.79%
Face Value
—
EPS
$-3.79
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
834
Beta
1.09
Debt / Equity
-0.89
Current Ratio
2.77
Quick Ratio
2.68
Forward P/E
283.26
Price / Sales
28.8
Enterprise Value
$15.75 B
EV / EBITDA
-31.7
EV / Revenue
31.36
Rating
Strong Buy
Target Price
$100.61
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
| 2. | Nuvalent, Inc. | $107.99 | — | $8.48 B | — | -31.35% | -36.7% | $113.02 / $63.55 | $15.96 |
| 3. | Alumis Inc. | $24.71 | — | $3.18 B | — | -134.01% | -86.68% | $30.6 / $2.76 | $2.88 |
| 4. | Vyome Holdings, Inc. | $2.35 | — | $16.49 M | — | -73.02% | 1053.07% | $56.36 / $1.75 | $0.41 |
| 5. | Editas Medicine, Inc. | $3.57 | — | $349.4 M | — | -70.81% | -1.98% | $4.54 / $1.23 | $0.28 |
| 6. | Gossamer Bio, Inc. | $0.42 | — | $98.57 M | — | -150.03% | 365.33% | $3.87 / $0.32 | $-0.53 |
| 7. | Vera Therapeutics, Inc. | $41.61 | — | $3.02 B | — | -46.31% | -50.71% | $56.05 / $18.76 | $8.48 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 154.18 M | 120.7 M | 110.56 M | 116.63 M | 5.88 M | — |
| Operating Profit | -128.43 M | -136.36 M | -133.47 M | -103.8 M | -221.33 M | — |
| Net Profit | -192.86 M | -182.74 M | -181.9 M | -167.42 M | -265.05 M | — |
| EPS in Rs | -0.99 | -0.94 | -0.94 | -0.86 | -1.37 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 502.08 M | 221.9 M | 9.3 M | 77.65 M |
| Operating Profit | -502.06 M | -577.37 M | -599.44 M | -468.44 M |
| Net Profit | -724.93 M | -535.76 M | -643.2 M | -481.18 M |
| EPS in Rs | -3.74 | -2.76 | -3.32 | -2.48 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 936.02 M | 919.34 M | 546.38 M | 623.04 M |
| Total Liabilities | 3.01 B | 2.38 B | 1.89 B | 1.87 B |
| Equity | -2.09 B | -1.47 B | -1.35 B | -1.25 B |
| Current Assets | 797.75 M | 720.69 M | 477.59 M | 548.85 M |
| Current Liabilities | 287.97 M | 154.4 M | 143.84 M | 121.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -445.91 M | -520.73 M | -527.72 M | -419.49 M |
| Investing CF | -24.49 M | 60.78 M | 54.03 M | 453.15 M |
| Financing CF | 359.29 M | 748.46 M | 451.54 M | -13.13 M |
| Free CF | -455.5 M | -529.63 M | -529.03 M | -425.81 M |
| Capex | -9.59 M | -8.91 M | -1.31 M | -6.32 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 2285.27% | -88.02% | — | — |
| Earnings Growth % | 16.7% | -33.67% | — | — |
| Profit Margin % | -241.44% | -6913.92% | -619.7% | — |
| Operating Margin % | -260.19% | -6443.56% | -603.28% | — |
| Gross Margin % | 98.25% | 73.71% | 95.58% | — |
| EBITDA Margin % | -196.86% | -6078.34% | -511.85% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.